Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SSR180575 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 25 mg SSR180575 | EXPERIMENTAL | orally once daily for 24 weeks |
| 100 mg SSR180575 | EXPERIMENTAL | orally once daily for 24 weeks |
| Placebo | PLACEBO_COMPARATOR | orally once daily for 24 weeks |
| Name | Type | Description |
|---|---|---|
| SSR180575 | DRUG | Oral, once daily dosing |
| Placebo | DRUG | Oral, once daily dosing |
Inclusion Criteria: * Patients diagnosed with Diabetes Mellitus, type I or II, treated or untreated * Diabetic neuropathy treated or untreated Exclusion Criteria: * Patients with unstable glycemic control * Patients who have been hospitalized for a diabetes complication in the 3 months prior to r...
SSR180575 is an investigational small molecule being developed for diabetic neuropathies, a type of nerve damage caused by diabetes. It is currently in Phase 2 clinical development and has not been approved by the FDA.
SSR180575 is being developed by Sanofi, a multinational pharmaceutical company listed on the stock exchange under the ticker SNY. The drug is currently in Phase 2 clinical trials for diabetic neuropathies.
SSR180575 is in Phase 2 clinical development. It is an investigational drug for diabetic neuropathies and has not yet been approved by regulatory authorities. One Phase 2 trial has been completed.
SSR180575 has one completed Phase 2 clinical trial, identified as NCT00502515, titled 'Dose-effect of SSR180575 in Diabetic Neuropathy'. This randomized, double-blind, placebo-controlled study enrolled 309 participants in the United States.
No, SSR180575 is not FDA approved. It is an investigational drug currently in Phase 2 clinical development for diabetic neuropathies. The drug has completed one Phase 2 trial but has not yet received regulatory approval.